熱門資訊> 正文
Tiziana Life Sciences宣布鼻内Foralumab治疗中度阿尔茨海默病患者的免疫学结果
2025-07-21 19:02
- Transcriptional analysis of white blood cells before and after foralumab therapy revealed profound immune modulatory effects. Significant changes were observed in CD4 cells, CD8 cells, and monocytes, underscoring the broad impact of nasal foralumab on immune cell profiles. These results are consistent with improvement in microglia PET scans conducted at the time of immune analysis which demonstrated a marked reduction in inflammation following nasal foralumab (Clin Nuclear Med) showing a link between immune effects and resolution of brain inflammation.
- In an unexpected discovery, the analysis revealed an increase in phagocytosis markers in classical monocytes, suggesting that nasal foralumab may enhance their ability to clear amyloid plaques. This unexpected effect may open new avenues for treating Alzheimer's Disease by targeting both inflammation and amyloid accumulation
推薦文章
美股機會日報 | 8月非農大幅低於預期！納指期貨短線拉漲約0.7%；特斯拉盤前漲近2%
一周財經日曆 | 事關降息！中美5月CPI、PPI重磅出爐！新股「超購王」大行科工下周上市
高盛：降新鴻基地產目標價至96港元 評級「買入」
特朗普白宮宴請硅谷巨頭 各大公司CEO紛紛重申在美投資承諾
非農前糟糕就業數據引爆降息預期 10年期美債收益率創四個月新低
AI收入超預期！芯片巨頭博通交出滿分財報 神祕百億訂單帶來驚喜
Lululemon Athletica連續第二次下調全年業績指引 盤后股價一度暴跌超15%
9月5日外盤頭條：馬斯克回絕白宮科技CEO晚宴邀請 波音罷工持續無奈招募替代工人 露露檸檬股價盤后暴跌10%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
